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@yahoo.com (V. GAbstract A rapid and sensitive liquid chromatography–tandem mass spectrometric (LC–MS/MS)
assay method has been developed and fully validated for the simultaneous quantiﬁcation of
pravastatin and aspirin in human plasma. Furosemide was used as an internal standard. Analytes
and the internal standard were extracted from human plasma by liquid–liquid extraction technique
using methyl tertiary butyl ether. The reconstituted samples were chromatographed on a Zorbax
SB-C18 column by using a mixture of 5 mM ammonium acetate buffer and acetonitrile (20:80, v/v) as
the mobile phase at a ﬂow rate of 0.8 mL/min. The calibration curve obtained was linear (rZ0.99)
over the concentration range of 0.50–600.29 ng/mL for pravastatin and 20.07–2012.00 ng/mL for
aspirin. Method validation was performed as per FDA guidelines and the results met the acceptance
criteria. A run time of 2.0 min for each sample made it possible to analyze more than 400 human
plasma samples per day. The proposed method was found to be applicable to clinical studies.
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1. Introduction
Management of the impaired lipid metabolism and inﬂamma-
tion in coronary artery patients is very important [1]. Hyperli-
pidemia is a major cause of atherosclerosis and atherosclerosis-
associated conditions such as coronary heart disease, ischemic
cerebrovascular disease and peripheral vascular disease [2].
Hyperlipidemia is characterized by elevated triglyceride
levels and decreased high-density lipoprotein cholesterol
(HDL-C) levels, with increase in the low-density lipoprotein
cholesterol (LDL-C) levels. Achievement of cholesterol levels
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therapy [3–5].
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors (statins) are the most commonly used
drugs in the treatment of hyperlipidemia. The statins competi-
tively inhibit HMG-coenzyme A reductase, which is involved
in the rate limiting step of cholesterol biosynthesis, thereby
inhibits the mevalonate synthesis [6,7]. Statins induce reduc-
tion in the LDL-C, which is milestone in the hyperlipedemia
therapy, and lead to reduction in the cardiovascular morbidity
and mortality [8]. Pravastatin is a hydrophilic liver-speciﬁc
inhibitor of HMG-CoA reductase and is characterized one of
the best among the statins due to its hydrophilic in nature
[9–11]. The lipid-lowering effect is mainly due to reversible
inhibition of HMG-CoA reductase activity and by inhibiting
the LDL production. Pravastatin is administered orally as the
sodium salt and undergoes extensive ﬁrst pass metabolism in
liver [12].
Aspirin is one of the most widely used anti-inﬂammatory
agents. The anti-inﬂammatory activity and anti-thrombotic
activity are mainly due to its reversible inhibition of the
cyclooxygenase. Cyclooxygenase catalyzes the formulation of
thromboxane and prostacyclin which has opposite effects on
aggregation and vasodilatation. At low doses (less than 100 mg)
aspirin selectively inhibits the formation of thromboxane [13].
Pravastatin in combination with aspirin reduces cardiovascular
risk. The more widespread and appropriate use of both
pravastatin and aspirin in secondary prevention of cardiovas-
cular disease will avoid large numbers of premature deaths [14].
A combination of buffered aspirin tablet with pravastatin
sodium (Pravigard PAC, Bristol-Myers Squibb Company,
USA) is commercially available in the market.
To date, no method is reported for the simultaneous
quantiﬁcation of pravastatin and aspirin in any of the
matrices. We felt that this simultaneous estimation method
will help the researchers as the two drugs used in this method
is available in the market with mixed combination. In this
report we describe the development and validation of a simple,
rapid and reproducible analytical method for the simultaneous
analysis of pravastatin and aspirin concentrations in human
plasma. This method provides high degree of accuracy,
sensitivity and speciﬁcity by simple liquid–liquid extraction
based on liquid chromatography separation and detection by
electrospray-tamdem mass spectrometry. The application of
this assay method to a clinical pharmacokinetic study in
healthy male volunteers following oral administration of
pravastatin and aspirin is described.2. Experimental
2.1. Chemicals and reagents
The reference sample of aspirin (100.0%) was purchased form
LGC Promochem, India, whereas pravastatin (97.8%) from
Neucon Pharma Ltd, India. Furosemide (99.8%) used as an
internal standard (IS) in this study, was obtained from Vivan
Life Sciences, Mumbai, India. Water used for the LC–MS/MS
analysis was prepared from Milli Q water puriﬁcation system
procured from Millipore (Bangalore, India). Acetonitrile and
methanol were of HPLC grade and purchased from J.T Baker
(Phillipsburg, USA). Analytical grade ammonium acetate andformic acid were purchased from Merck (Merck, Mumbai,
India). Methyl tertiary butyl ether was purchased from J.T.
Baker (Phillipsburg, USA). The control K2-EDTA human
plasma sample was procured from Doctor’s Pathological Lab
(Hyderabad, India).
2.2. Instrumentation and chromatographic conditions
An HPLC system (Shimadzu, Kyoto, Japan) consisting of a
Zorbax SB-C18 column (50 mm 4.6 mm, 3.5 mm; Agilent
Technologies, Santa Clara, CA, USA ), a binary LC-20AD
prominence pump, an auto sampler (SIL-HTc) and a solvent
degasser (DGU-20A3) was used for the study. Aliquots of the
processed samples (25 mL) were injected into the column,
which was kept at 30 1C. The isocratic mobile phase, a mixture
of 5 mM ammonium acetate buffer and acetonitrile (20:80, v/v),
was delivered at 0.8 mL/min into the electrospray ionization
chamber of the mass spectrometer. Quantitation was achieved
with MS-MS detection in negative ion mode for both the
analytes and the internal standard using a MDS Sciex API-
4000 mass spectrometer (Foster City, CA, USA) equipped
with a Turboionspray TM interface at 500 1C. The ion spray
voltage was set at 4500 V. The source parameters viz. the
nebulizer gas, curtain gas, auxillary gas and collision gas were
set at 40, 20, 35 and 5 psi, respectively. The compound
parameters viz. the declustering potential (DP), collision
energy (CE), entrance potential (EP) and collision cell exit
potential (CXP) were 40, 35, 10, 5 V for pravastatin,
10, 9, 10, 5 V for aspirin and 55, 25, 10, 15 V for
IS. Detection of the ions was carried out in the multiple-
reaction monitoring mode (MRM), by monitoring the transi-
tion pairs of m/z 423.3 precursor ion to the m/z 100.8 for
pravastatin, m/z 179.0 precursor ion to the m/z 136.8 for
aspirin and m/z 329.1 precursor ion to the m/z 285.0 product
ion for the IS. Quadrupoles Q1 and Q3 were set on unit
resolution. The analysis data obtained were processed by
Analyst softwareTM (version 1.4.2).
2.3. Standard solutions
Primary stock solutions of pravastatin and aspirin for pre-
paration of standard calibration curve and quality control
(QC) samples were prepared from separate weighing. The
stock solution of pravastatin (1 mg/mL) was prepared in
methanol, whereas aspirin (1 mg/mL) was prepared in 0.2%
formic acid in acetonitrile and these stocks were stored at
2–8 1C; they were found to be stable for 23 day. From these
stock solutions, appropriate dilutions were made using a
mixture of acetonitrile and water (60:40, v/v) as a diluent, to
produce working standard solutions of pravastatin and
aspirin. The primary stock solution of furosemide (1 mg/mL)
was prepared in methanol. A working concentration of the
internal standard (1 mg/mL) solution was prepared in the
diluent (acetonitrile and water, 60:40, v/v).
2.4. Preparation of calibration curve standards and quality
control samples
Calibration samples were prepared by spiking 950 mL of
control human plasma with the appropriate working standard
solution of the each analyte (25 mL dilution of pravastatin and
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70 mL aliquot of 150 mg/mL potassium ﬂuoride in 1 mL of
plasma) consisting of a set of nine non-zero concentrations
ranging from 0.50 to 600.29 ng/mL for pravastatin and 20.07
to 2012.00 ng/mL for aspirin were prepared. Samples for the
determination of precision and accuracy were prepared by
spiking control human plasma in bulk with pravastatin and
aspirin at appropriate concentrations and 400 mL plasma
aliquots were distributed into different tubes. The QC samples
prepared for each analyte were: for pravastatin – 0.50
(LLOQ), 1.50 (LQC), 96.22 (MQC1), 300.70 (MQC2) and
400.93 ng/mL (HQC); and for aspirin – 20.09 (LLOQ), 60.16
(LQC), 388.13 (MQC1), 1008.13 (MQC2) and 1600.20 ng/mL
(HQC). All the samples were stored at 7075 1C for
subsequent use.
2.5. Sample processing
A 250-mL volume of the plasma sample was transferred to a
15-mL glass test tube, and to it 25 mL of working concentra-
tion of the IS (1 mg/mL) was spiked. To this 25 mL of 1%
formic acid was added. After vortexing for 30 s, a 4-mL
aliquot of the methyl tertiary butyl ether was added using
Dispensette Organic (Brand GmbH, Wertheim, Germany) as
the extraction solvent. The sample was shaken for 10 min
using a reciprocating shaker (Scigenics Biotech, Chennai,
India) and then centrifuged for 5 min at 4000 rpm using a
Heraeus Megafuse 3SR centrifuge (Japan). The organic layer
(3 mL) was transferred to a 15-mL glass test tube and
evaporated at 40 1C under a stream of nitrogen. The dried
extract was reconstituted with 500-mL of the mobile phase and
a 25-mL aliquot was injected into the column. Sample proces-
sing was done in ice-water batch. All procedures were
conducted at about 4 1C in an ice bath.
2.6. Method validation
A thorough validation of the method was carried out as per
the US FDA guidelines [15]. The method was validated for
selectivity, sensitivity, matrix effect, linearity, precision, accu-
racy, recovery, dilution integrity and stability. Selectivity of
the method was assessed by analyzing eight blank (including
lipemic and hemolytic plasma) human plasma matrix samples.
The responses of the interfering substances or background
noises at the retention time of the aspirin and pravastatin are
acceptable if they are less than 20% of the response of the
lowest standard curve point or LLOQ. The responses of the
interfering substances or background noise at the retention
time of the internal standard are acceptable if they are less
than 5% of the response of the working internal standard.
Sensitivity was established from the background noise or
response from six spiked LLOQ samples. The six replicates
should have a precision of r20% and an accuracy of 720%.
Matrix effect is investigated to ensure that precision, selectivity
and sensitivity are not compromised by the matrix. Matrix
effect was checked with eight different lots of K2-EDTA
plasma. Three replicate samples each of LQC and HQC were
prepared from different lots of plasma (48 QC samples in total).
Linearity was tested for pravastatin and aspirin in the
concentration range of 0.50–600.29 and 20.07–2012.00 ng/mL,
respectively. For the determination of linearity, standardcalibration curves containing at least 9 points (non-zero
standards) were plotted and checked. In addition, blank plasma
samples were also analyzed to conﬁrm the absence of direct
interferences, but these data were not used to construct the
calibration curve. The acceptance limit of accuracy for each of
the back-calculated concentrations is 715% except LLOQ,
where it is720%. For a calibration run to be accepted at least
67% of the standards, the LLOQ and ULOQ are required to
meet the acceptance criterion otherwise; the calibration curve
was rejected. Five replicate analyses were performed on each
calibration standard. The samples were run in the order from
low to high concentration.
Intra-assay precision and accuracy were determined by
analyzing six replicates at ﬁve different QC levels in the same
day two runs. Inter-assay precision and accuracy were deter-
mined by analyzing six replicates at ﬁve different QC levels on
ﬁve different runs. The acceptance criteria includes accuracy
within 715% deviation (SD) from the nominal values, except
LLOQ QC, where it should be 720% and a precision of
r15% relative standard deviation (RSD), except for LLOQ
QC, where it should be r20%. Whereas batch acceptance
criteria includes 67% for over all quality control samples and
50% at each level respectively.
Recovery of the analytes from the extraction procedure was
determined by comparing the peak areas of the analytes in
spiked plasma samples (six each of low, middle, and high QCs)
with those of the analytes in samples prepared by spiking the
extracted drug-free plasma samples with the same amounts of
the analytes at the step immediately prior to chromatography.
Similarly, recovery of the IS was determined by comparing the
mean peak areas of the extracted QC samples (n¼6) with those
of the IS in samples prepared by spiking the extracted drug-free
plasma samples with the same amounts of IS (1 mg/mL) at the
step immediately prior to chromatography.
The dilution integrity exercise is performed with an aim to
validate the dilution test to be carried out on higher analyte
concentrations above the ULOQ during real time analysis of
subject samples. Dilution integrity experiment was carried out
at 1.7 times the ULOQ concentration for both the analytes.
Six replicates each of 1/2 and 1/4th concentrations were
prepared and their concentrations were calculated by applying
the dilution factor 2 and 4.
Stability tests were conducted to evaluate the analyte
stability in stock solutions and in plasma samples under
different conditions. The stock solution stability at room
temperature and refrigerated conditions (2–8 1C) was per-
formed by comparing the area response of the analytes
(stability samples) with the response of the sample prepared
from fresh stock solution. Bench top stability in ice water bath
(5 h), processed samples stability (Autosampler stability for
46 h, wet extract stability for 43 h and reinjection stability for
26 h), freeze-thaw stability in ice water bath (three cycles),
long-term stability (56 day) were performed at LQC and HQC
levels using six replicates at each level. Samples were con-
sidered to be stable if assay values were within the acceptable
limits of accuracy (715% SD) and precision (r15% RSD).2.7. Pharmacokinetic study design
A pharmacokinetic study on the drug was performed in
healthy male subjects (n¼12). The ethics committee approved
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written consent. Blood samples (1 mL) were collected follow-
ing oral administration of 40 mg tablet of pravastatin and
81 mg tablet of aspirin at pre-dose and 0.083, 0.167, 0.25, 0.33,
0.417, 0.5, 0.67, 0.83, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 6, 8, 12,
16 and 24 h, in K2-EDTA vacutainer collection tubes (BD,
Franklin, NJ, USA) containing a 70 mL aliquot of 150 mg/mL
potassium ﬂuoride (to minimize the hydrolysis of aspirin to
salicylic acid in blood) [16]. The tubes were centrifuged at
3200 rpm for 10 min at 4 1C and the plasma was collected.
Immediately after collection, the plasma samples were sub-
jected to ﬂash-freezing and stored at –70 1C till their use.
Plasma samples were spiked with the IS and processed as per
the extraction procedure described earlier. Along with the
clinical samples, the QC samples at low, middle 1, middle 2
and high concentration levels were assayed in triplicate and
were distributed among the unknown samples in the analytical
run; not more than 33% of the QC samples were greater than
715% of the nominal concentration. Plasma concentration-
time proﬁle of each analyte was analyzed by non-compart-
mental method using WinNonlin Version 5.1.Figure 1 Typical MRM chromatograms of pravastatin (left
panel) and the IS (right panel) in (A) human blank plasma and
(B) human plasma spiked with IS (C) a LLOQ sample along
with IS.3. Results
3.1. Mass spectrometry
Mass parameters were tuned in negative ionization modes for
the analytes. Good response was achieved in negative ioniza-
tion mode. Data from the MRM mode were considered to
obtain better selectivity. Deprotonated form of each analyte
and IS, [M–H] – ion, was the parent ion in the Q1 spectrum
and was used as the precursor ion to obtain Q3 product ion
spectra. The most sensitive mass transition was monitored
from m/z 423.3 to 100.8 for pravastatin, from m/z 179.0 to
136.8 for aspirin and from m/z 329.1 to 285.0 for the IS. As
earlier publications have discussed the details of fragmentation
patterns of pravastatin [17], aspirin [18] and the IS [19], we are
not presenting the data pertaining to this.
3.2. Method development
The chromatographic conditions, especially the composition
of mobile phase, were optimized through several trials to
achieve good resolution and symmetric peak shapes for the
analytes as well as a short run time. Separation was attempted
using various combinations of acetonitrile and buffer with
varying contents of each component on different columns like
C8 and C18 of different makes like Chromolith, Hypersil,
Hypurity advance, Zorbax, Kromasil and Intertsil. It was
found that a mixture of 5 mM ammonium acetate buffer and
acetonitrile (20:80, v/v) could achieve this purpose and the was
ﬁnally adopted as the mobile phase. Zorbax SB-C18 column
(50 mm 4.6 mm, 3.5 mm) gave a good peak shape and
response even at LLOQ level for both the analytes and the
IS. The retention time of pravastatin, aspirin and IS was low
enough (1.12, 0.79 and 0.60 min) allowing a small run time of
2.0 min.
Liquid–liquid extraction (LLE) technique was employed for
the sample preparation in this work. LLE is helpful in
producing a spectroscopically clean sample and avoiding the
introduction of non-volatile materials onto the column andMS system and also minimizing the experimental cost. Clean
samples are essential for minimizing ion suppression and
matrix effect in LC–MS/MS. Among the different solvents
checked alone and in combination for their suitability, tertiary
butyl methyl ether was found to be optimal, which can
produce a clean chromatogram for a blank sample and yield
the reproducibly recovery for the analytes from the plasma.
Both pravastatin and aspirin are acidic in nature; therefore
addition of formic acid improves their extraction efﬁciently.
A good internal standard must mimic the analyte during
extraction and compensate for any analyte on the column.
Isotope-labeled analyte was not available to serve as IS, so, in
the initial stages of this work, several compounds were
investigated to ﬁnd a suitable IS and ﬁnally furosemide was
found to be best for the present purpose. Furosemide was
evaluated for precision and accuracy and extraction recovery
of the internal standard was good and reproducible.
3.3. Selectivity and chromatography
The degree of interference by endogenous plasma constituents
with the analytes and the IS was assessed by inspection of
chromatograms derived from processed blank plasma sample.
As shown in Figs. 1 and 2, no signiﬁcant direct interference in
the blank plasma traces was observed from endogenous
substances in drug-free plasma at the retention time of the
analytes and the IS.
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The lowest limit of reliable quantiﬁcation for the analytes was
set at the concentration of the LLOQ. The precision and
accuracy at LLOQ concentration were found to be 5.16% and
94.25% for pravastatin, 7.49% and 93.90% for aspirin.
3.5. Matrix effect
No signiﬁcant matrix effect was observed in all the eight
batches of human plasma for the analytes at LQC and HQCFigure 2 Typical MRM chromatograms of aspirin (left panel)
and the IS (right panel) in (A) human blank plasma and (B)
human plasma spiked with IS (C) a LLOQ sample along with IS.
Table 1 Precision and accuracy of the method for determining p
Analytes Concentration
added (ng/mL)
Intra-day precision and accuracy
(n¼12; 6 from each batch)
Concentration found
(mean; ng/mL)
Precision
(%)
Pravastatin 0.50 0.52 2.22
1.50 1.50 5.96
96.22 96.63 5.46
300.70 281.12 4.24
400.93 396.27 4.55
Aspirin 20.09 19.17 4.99
60.16 64.86 3.94
388.13 366.73 6.17
1008.13 919.57 2.73
1600.20 1481.53 3.18concentrations. The precision and accuracy for pravastatin
at LQC concentration were found to be 2.96% and 96.95%,
and at HQC level they were 6.39% and 93.08%, respectively.
Similarly, the precision and accuracy for aspirin at LQC
concentration were found to be 3.67% and 97.22% and at
HQC level they were 6.32% and 101.02%, respectively.
3.6. Linearity
Nine-point calibration curve was found to be linear over the
concentration range of 0.50–600.29 ng/mL for pravastatin and
20.07–2012.00 ng/mL for aspirin. After comparing the two
weighting models (1/x and 1/x2), a regression equation with a
weighting factor of 1/x2 of the drug to the IS concentration
was found to produce the best ﬁt for the concentration-
detector response relationship for both the analytes in
human plasma. The mean correlation coefﬁcient of the
weighted calibration curves generated during the validation
was 0.99.
3.7. Precision and accuracy
Accuracy and precision data for intra- and inter-day plasma
samples for pravastatin and aspirin are presented in Table 1.
The assay values on both the occasions (intra- and inter-day)
were found to be within the accepted variable limits.
3.8. Extraction efﬁciency
A simple liquid/liquid extraction with methyl tertiary butyl
ether proved to be robust and provided cleanest samples. The
recoveries of analytes and the IS were good and reproducible.
The mean overall recoveries (with the precision range) of
pravastatin, aspirin and IS were 61.6572.39% (1.75–4.52%),
51.2471.26% (1.88–3.49%) and 65.4671.60% (1.60–3.69%),
respectively.
3.9. Dilution integrity
The upper concentration limits can be extended to 960.46 ng/mL
for pravastatin and 3219.20 ng/mL for aspirin by 1/2 and 1/4ravastatin and aspirin in plasma samples.
Inter-day precision and accuracy
(n¼30; 6 from each batch)
Accuracy
(%)
Concentration found
(mean; ng/mL)
Precision
(%)
Accuracy
(%)
103.61 0.51 7.28 101.61
99.90 1.49 6.27 99.58
100.42 94.06 7.29 97.75
93.49 282.99 4.42 94.11
98.84 395.66 5.24 98.68
95.41 19.56 8.34 97.36
107.81 65.03 4.89 108.10
94.49 384.37 7.04 99.03
91.22 937.73 6.69 93.02
92.58 1488.89 4.17 93.04
Figure 3 Mean plasma concentration-time proﬁle of (A) pravas-
tatin and (B) aspirin in human plasma following oral dosing of
40 mg pravastatin sodium and 81mg aspirin tablets to healthy
volunteers (n¼12).
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calculated concentrations for 1/2 and 1/4 dilution samples were
within 85–115% of their nominal value. The coefﬁcients of
variation (%CV) for 1/2 and 1/4 dilution samples were less
than 15%.
3.10. Stability studies
In the different stability experiments carried out viz. bench top
stability (5 h at ice water bath), autosampler stability (46 h),
freeze-thaw stability (3 cycles at ice water bath), reinjection
stability (26 h), wet extract stability (43 h at 2–8 1C) and long-
term stability at 70 1C for 56 day the mean % nominal
values of the analytes were found to be within 715% of the
predicted concentrations for the analytes at their LQC and
HQC levels (Table 2). Thus, the results were found to be
within the acceptable limits during the entire validation.
Stock solutions of pravastatin, aspirin and the IS were
found to be stable for 23 day at 2–8 1C. The percentage
stability (with the precision range) of pravastatin, aspirin and
the IS was 103.78% (3.32–3.56%), 95.22% (2.66–2.72%) and
98.74% (2.01–3.38%), respectively.
3.11. Pharmacokinetic study results
In order to verify the sensitivity and selectivity of this method
in a real-time situation, the present method was used to test
for pravastatin and aspirin in human plasma samples collected
from healthy male volunteers (n¼12). The mean plasma
concentrations vs time proﬁles of pravastatin and aspirin is
shown in Fig. 3(A) and (B), respectively. PharmacokineticTable 2 Stability samples result for pravastatin and aspirin in human plasma (n¼6).
Stability test Pravastatin Aspirin
QC (spiked
concentration,
ng/mL)
Mean7SD
(ng/mL)
Accuracy/
stability
(%)
Precision
(%)
QC (spiked
concentration,
ng/mL)
Mean7SD
(ng/mL)
Accuracy/
stability
(%)
Precision
Aautosampler
stability (at 5 1C
for 46 h)
1.50 1.4470.04 95.61 2.47 60.16 58.0971.14 96.56 1.96
400.93 367.64722.05 91.70 6.00 1600.20 1543.25738.11 96.44 2.47
Wet extract
stability (at 2–
8 1C for 43 h)
1.50 1.4870.02 98.91 1.13 60.16 57.69 71.66 95.89 2.87
400.93 380.29712.08 94.85 3.18 1600.20 1531.53734.01 95.71 2.22
Bench top stability
(5 h in ice water
bath)
1.50 1.4470.10 95.80 6.86 60.16 55.9074.20 92.92 7.51
400.93 377.88711.20 94.25 2.96 1600.20 1471.28712.99 91.94 0.88
Freeze-thaw
stability
1.50 1.4570.05 96.78 3.24 60.16 54.57 71.90 90.71 3.49
400.93 376.73713.60 93.96 3.61 1600.20 1474.95718.77 92.17 1.27
Reinjection
stability (26 h)
1.50 1.5370.05 104.12 3.46 60.16 63.19 72.15 98.20 3.40
400.93 393.91720.88 103.41 5.30 1600.20 1485.15716.10 101.41 1.08
Long-term 1.50 1.4570.04 93.16 2.70 60.16 56.7972.84 101.13 5.00
Stability (at –70 1C
for 56 day)
400.93 410.98715.27 106.20 3.72 1600.20 1575.42766.27 95.33 4.21
Table 3 Pharmacokinetic parameters of pravastatin and
aspirin (n¼12, Mean7SD).
Parameter Pravastatin Aspirin
tmax (h) 0.6070.17 0.6670.21
Cmax (ng/mL) 94.65746.10 872.197209.86
AUC0–t (ng h/mL) 153.46761.05 1175.097422.10
AUC0–inf (ng h/mL) 156.99761.99 1188.227433.03
t1/2 (h) 0.3670.32 1.0370.27
Kel (h1) 2.5871.06 0.7270.18
S.R. Polagani et al.212results of pravastatin and aspirin are presented in Table 3.
Pharmacokinetic results of pravastatin were in close proximity
when compared with earlier reported values [20]. To date, to
the best of our knowledge, no pharmacokinetic data on aspirin
after oral administration of 81 mg tablet have been reported in
the literature.4. Discussion
To date, no reports are available for the simultaneous
quantiﬁcation of pravastatin and aspirin in any of the
matrices. Validated methods are essential for the determina-
tion of pravastatin and aspirin concentrations in human
plasma for bioequivalence studies. This is, to the best of our
knowledge, the ﬁrst validation report for an LC–MS/MS
method for the simultaneous assay of pravastatin and aspirin
using the convenience of a single-step extraction procedure.
The reported method is simple, rugged and rapid due to
utilization of short run time of 2.0 min for each sample
analysis. The method uses single IS with simple sample
preparation technique (LLE).5. Conclusion
The LC–MS/MS assay reported in this paper is rapid, simple,
speciﬁc and sensitive for simultaneous quantiﬁcation of
pravastatin and aspirin in human plasma and is fully validated
according to commonly acceptable FDA guidelines. The
method showed suitability for pharmacokinetic studies in
humans. The cost-effectiveness, simplicity of the assay and
usage of liquid–liquid extraction, and sample turnover rate of
less than 2.0 min per sample, make it an attractive procedure
in high-throughput bioanalysis of pravastatin and aspirin.
From the results of all the validation parameters, we can
conclude that the developed method can be useful for BA/BE
studies and routine therapeutic drug monitoring with the
desired precision and accuracy.Acknowledgments
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